187 related articles for article (PubMed ID: 32103356)
1. Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma.
Mitsunaga S; Kasamatsu E; Machii K
Support Care Cancer; 2020 Nov; 28(11):5271-5279. PubMed ID: 32103356
[TBL] [Abstract][Full Text] [Related]
2. A Retrospective Cohort Study to Investigate the Incidence of Cachexia During Chemotherapy in Patients with Colorectal Cancer.
Shibata M; Fukahori M; Kasamatsu E; Machii K; Hamauchi S
Adv Ther; 2020 Dec; 37(12):5010-5022. PubMed ID: 33067699
[TBL] [Abstract][Full Text] [Related]
3. Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer.
Kays JK; Shahda S; Stanley M; Bell TM; O'Neill BH; Kohli MD; Couch ME; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):673-684. PubMed ID: 29978562
[TBL] [Abstract][Full Text] [Related]
4. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review.
Ozola Zalite I; Zykus R; Francisco Gonzalez M; Saygili F; Pukitis A; Gaujoux S; Charnley RM; Lyadov V
Pancreatology; 2015; 15(1):19-24. PubMed ID: 25524484
[TBL] [Abstract][Full Text] [Related]
5. Cachexia worsens prognosis in patients with resectable pancreatic cancer.
Bachmann J; Heiligensetzer M; Krakowski-Roosen H; Büchler MW; Friess H; Martignoni ME
J Gastrointest Surg; 2008 Jul; 12(7):1193-201. PubMed ID: 18347879
[TBL] [Abstract][Full Text] [Related]
6. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
Al Haddad AH; Adrian TE
Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
[TBL] [Abstract][Full Text] [Related]
7. The differential effects of sarcopenia and cachexia on overall survival for pancreatic ductal adenocarcinoma patients following pancreatectomy: A retrospective study based on a large population.
Shen XD; Wang X; Zheng ZJ; Chen YH; Tan CL; Liu XB; Ke NW
Cancer Med; 2023 May; 12(9):10438-10448. PubMed ID: 36938648
[TBL] [Abstract][Full Text] [Related]
8. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Akahori T; Sho M; Yanagimoto H; Satoi S; Nagai M; Nishiwada S; Nakagawa K; Nakamura K; Yamamoto T; Hirooka S; Yamaki S; Ikeda N
Oncologist; 2019 Jun; 24(6):749-e224. PubMed ID: 30679316
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
Gutierrez-Sainz L; Viñal D; Villamayor J; Martinez-Perez D; Garcia-Cuesta JA; Ghanem I; Custodio A; Feliu J
Clin Transl Oncol; 2021 Sep; 23(9):1838-1846. PubMed ID: 33866520
[TBL] [Abstract][Full Text] [Related]
10. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
[TBL] [Abstract][Full Text] [Related]
11. A retrospective cohort study to investigate the incidence of cancer-related weight loss during chemotherapy in gastric cancer patients.
Fukahori M; Shibata M; Hamauchi S; Kasamatsu E; Machii K
Support Care Cancer; 2021 Jan; 29(1):341-348. PubMed ID: 32361831
[TBL] [Abstract][Full Text] [Related]
12. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Gulhati P; Prakash L; Katz MHG; Wang X; Javle M; Shroff R; Fogelman D; Lee JE; Tzeng CD; Lee JH; Weston B; Tamm E; Bhosale P; Koay EJ; Maitra A; Wang H; Wolff RA; Varadhachary GR
Ann Surg Oncol; 2019 Feb; 26(2):619-627. PubMed ID: 30324485
[TBL] [Abstract][Full Text] [Related]
13. Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma.
Insulander J; Sanjeevi S; Haghighi M; Ivanics T; Analatos A; Lundell L; Del Chiaro M; Andrén-Sandberg Å; Ansorge C
Br J Surg; 2016 Aug; 103(9):1200-8. PubMed ID: 27250937
[TBL] [Abstract][Full Text] [Related]
14. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
[TBL] [Abstract][Full Text] [Related]
15. Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis.
Irie H; Suzuki R; Takagi T; Sugimoto M; Konno N; Sato Y; Hikichi T; Nakamura J; Hashimoto M; Ohira H
Cancer Chemother Pharmacol; 2020 Mar; 85(3):517-523. PubMed ID: 31691078
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600
[TBL] [Abstract][Full Text] [Related]
17. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.
De Vita F; Ventriglia J; Febbraro A; Laterza MM; Fabozzi A; Savastano B; Petrillo A; Diana A; Giordano G; Troiani T; Conzo G; Galizia G; Ciardiello F; Orditura M
BMC Cancer; 2016 Sep; 16(1):709. PubMed ID: 27590845
[TBL] [Abstract][Full Text] [Related]
18. Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery.
Cameron ME; Underwood PW; Williams IE; George TJ; Judge SM; Yarrow JF; Trevino JG; Judge AR
Cancer Med; 2022 Jan; 11(1):50-60. PubMed ID: 34791809
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.
Chung KH; Ryu JK; Son JH; Lee JW; Jang DK; Lee SH; Kim YT
Gut Liver; 2017 Mar; 11(2):298-305. PubMed ID: 27965478
[TBL] [Abstract][Full Text] [Related]
20. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
